Pfizer leads busy bond week; GSK gets green light for U.K. expansion;

Pfizer

@FiercePharma: Roche unveils more plans for plant expansions in Switzerland. Story | Follow @FiercePharma

@TracyStaton: If AstraZeneca were Harry Potter, would that make Pfizer Voldemort? More | Follow @TracyStaton

@EricPFierce: China forewarns drugmakers. It's not messing around when it comes to bribery as a sales tool. More | Follow @EricPFierce

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

@CarlyHFierce: First, bribery. Now, China floats tax-evasion accusations against GlaxoSmithKline. News | Follow @CarlyHFierce

> Pfizer ($PFE) is leading a busy week of bond sales, issuing $4.5 billion. Report

> GlaxoSmithKline ($GSK) has won approval for its £100 million ($168 million) plans to expand a pharmaceutical plant in Worthing, U.K. More

> Endo ($ENDP) has acquired from Zogenix ($ZGNX) the rights to its Sumavel DosePro, a needle-free delivery system for migraine treatment. Release

> Forest Labs ($FRX) is selling its building in Commack, NY. Story

> Reckitt Benckiser, looking for deal approval, has applied to New Zealand's Commerce Commission seeking clearance to acquire Johnson & Johnson's ($JNJ) K-Y brand and product assets. More

> Indonesian herbal medicine maker Sido Muncul is buying pharmaceutical firm PT Berlico Mulia Farma for about 150 billion rupiah ($13.1 million). More

Medical Device News

@FierceMedDev: Water Street plans to grow a German specialty Dx company into a major player, through investment and M&A. ICYMI from FierceDiagnostics | Follow @FierceMedDev

@VarunSaxena2: It's official: Alere is spinning off its diagnostics biz. More | Follow @VarunSaxena2

@MichaelGFierce: From Harvard Research: Herpes-loaded stem cells used to kill brain tumors. More | Follow @MichaelGFierce

@EmilyWFierce: Gelesis brought in $12M for superabsorbent hydrogel technology that swells in the stomach to treat obesity. More from MedCityNews | Follow @EmilyWFierce

> Acufocus gears up for FDA scrutiny on corneal implant. Item

> It's official: Alere is spinning off its diagnostics biz. Article

> CMS closer to coverage for Abbott's MitraClip. More

Biotech News

@FierceBiotech: Why did Pfizer's big fiesta for palbociclib fizzle? Story | Follow @FierceBiotech

@JohnCFierce: Elotuzumab: Bristol-Myers nabs another 'breakthrough' cancer drug title. More | Follow @JohnCFierce

@DamianFierce: From yesterday: The redacted bit of Pfizer's letter sort of spells out their passive-aggressive strategy. Image | Follow @DamianFierce

@EmilyMFierce: Scientists can have an impact on the antibiotic crisis by engaging the public and talking to media, says Ian Lipkin. | Follow @EmilyMFierce

> AstraZeneca slaps down Pfizer's 'final' $119B takeover bid. More

> Boehringer, InterMune wow IPF field with a slate of groundbreaking trial data. Story

> Another animal health biotech plots an IPO. Item

CRO News

> WuXi wraps up construction on a new biologics shop. Item

> Bayer agrees to share trial data, but not without a list of caveats. Article

> PRA amps up its biologics footprint amid industry shift. Story

> Evotec's hybrid CRO approach pays off in Q1. More

> WuXi scores more double-digit growth amid its global expansion. Report

Biotech IT News

> Venter nabs AstraZeneca's R&D IT chief for Human Longevity. News

> Bayer, Boehringer extend access to clinical trial data. Item

> NIH lays out up to $20B in IT spending over coming decade. More

> HCL Tech adds Novartis to roster of Big Pharma clients. Story

> GSK signs up to access Metabolon's bioinformatics tools. Article

And Finally... Which is better at detecting cancer, a laboratory or a Labrador retriever? It could be the latter. Story

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…